This book covers foundational topics in the emerging field of radiopharmaceutical therapy. It is divided into three sections: fundamentals, deeper dives, and special topics. In the first section, the authors examine the field from a bird's-eye view, covering topics including the history of radiopharmaceutical therapy, the radiobiology of radiopharmaceutical therapy, and the radiopharmaceutical chemistry of both metallic and non-metallic radionuclides. The second section provides a more in-depth look at specific radiotherapeutics. Chapters include broader discussions of the different platforms for radiopharmaceutical therapy as well as more focused case studies covering individual radiotherapeutics. The third and final section explores a number of areas for further study, including medical physics, artificial intelligence, in vivo pretargeting, theranostic imaging, and the regulatory review process for radiotherapeutics. This book is the first of its kind and is useful for a broad audience of scientists, researchers, physicians, and students across a range of fields, including biochemistry, cancer biology, nuclear medicine, radiology, and radiation oncology.

Autorentext

Lisa Bodei, MD, PhD is a nuclear medicine physician with extensive experience and expertise in therapeutic and diagnostic applications of nuclear medicine in oncology, particularly with theranostics and the application of genomic technology to further defining the efficacy of theranostics. She is the Director of the Targeted Radionuclide Therapy Section of the Molecular Imaging and Therapy Service in the Department of Radiology, MSKCC. She has authored more than 200 peer-reviewed publications and serves on the editorial boards of several scientific journals.

Jason S. Lewis, PhD, is the Emily Tow Chair, Chief of the Radiochemistry and Imaging Sciences Service, and Director of the Radiochemistry and Molecular Imaging Probe Core Facility in the Department of Radiology, MSKCC. He heads a laboratory in the Sloan Kettering Institute's molecular pharmacology program and is a professor at the Gerstner Sloan Kettering Graduate School of BiomedicalSciences. He has published more than 300 papers, books, book chapters, and reviews on cancer imaging and therapy.

Brian M. Zeglis, PhD, received his scientific training at Yale University, the California Institute of Technology, and Memorial Sloan Kettering Cancer Center before starting his own lab at Hunter College of the City University of New York in 2015. His current research is focused on the synthesis, in vivo validation, and clinical translation of radiopharmaceuticals for the imaging and therapy of disease, with a particular emphasis on investigations at the intersection of radiochemistry and bioorthogonal chemistry.